Q&A: Oxford Pharmascience expects strong sales to continue - In a transformational year, drug reformulation specialist Oxford Pharmascience (LON:OXP) saw a 122% rise in revenues over the period. Chief executive Nigel Theobald explains why he believes this trend will continue in 2014. Proactive Investors: Explain a little bit more about whats been happening because how has this rise been achieved? Nigel Theobald: Were delighted that weve doubled sales again. Weve b... ow.ly/2D1fvm
Posted on: Fri, 17 Jan 2014 10:28:47 +0000
Recently Viewed Topics
© 2015